Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00227435 | Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis C | PHASE1 | COMPLETED | - | — | — | Feb 1, 2003 | Jul 1, 2004 | Apr 27, 2016 | 4 | United States |
| Name | Type | Description |
|---|---|---|
| val-mCyd | DRUG | - |
Inclusion Criteria: * Documented clinical history of chronic hepatitis C and compensated liver disease * No antiviral treatment for hepatitis C in the 6 months prior to the Screening visit Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Patient is pregnant or breastfee...